The WNK1–ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib
Adrián Sánchez‐Fdez(Instituto de Investigación Biomédica de Salamanca), Azucena Esparı́s-Ogando(Instituto de Investigación Biomédica de Salamanca)
Cited by 11
Related Papers
Therapeutic potential of ERK5 targeting in triple negative breast cancer
|Oncotarget|2014|48
Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
|npj Precision Oncology|2021|31
ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression
|International Journal of Molecular Sciences|2024|2